Skip to main content
. Author manuscript; available in PMC: 2015 Jan 13.
Published in final edited form as: Cancer Cell. 2014 Jan 13;25(1):37–48. doi: 10.1016/j.ccr.2013.12.004

Figure 8. Proposed model of how type I IFNs link the innate and adaptive anti-tumor immunity.

Figure 8

DAMPs released from Ab-sensitive tumor, but not Ab-resistant tumor after Ab therapy, will induce type I IFNs production. Ab-IFN mimics in situ type I IFN production in Ab-resistant tumor. Type I IFNs simultaneously increase DCs cross-presentation for better CTL responses, directly activate T cells and also induce PD-L1 expression to weaken the anti-tumor immunity. Ab-IFN combined with PD-L1 blockade maximizes the anti-tumor immune responses.